Albert Bourla, Pfizer CEO (Christopher Goodney/Bloomberg via Getty Images)
As GSK is forced to slam the brakes, Pfizer cruises ahead with a ‘breakthrough’ on RSV
Pfizer was a late arrival to the heavyweight Phase III fight to gain a first approval for an RSV vaccine, but the pharma giant has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
